Document is current
Any future updates will be listed below
-
Authors
Zhao, Shuang G. http://orcid.org/0000-0002-9166-6507
Bootsma, Matthew
Zhou, Stanley http://orcid.org/0000-0001-8187-0128
Shrestha, Raunak http://orcid.org/0000-0002-1144-1413
Moreno-Rodriguez, Thaidy http://orcid.org/0000-0003-3588-3889
Lundberg, Arian http://orcid.org/0000-0002-6630-2787
Pan, Chu
Arlidge, Christopher
Hawley, James R.
Foye, Adam
Weinstein, Alana S. http://orcid.org/0000-0002-1563-9072
Sjöström, Martin http://orcid.org/0000-0002-2629-9966
Zhang, Meng http://orcid.org/0000-0003-1042-6294
Li, Haolong http://orcid.org/0000-0002-8628-9698
Chesner, Lisa N.
Rydzewski, Nicholas R.
Helzer, Kyle T. http://orcid.org/0000-0003-3853-5564
Shi, Yue http://orcid.org/0000-0002-2860-2666
,
Bailey, Adina M.
Zhang, Li
Beer, Tomasz M.
Thomas, George
Chi, Kim N.
Gleave, Martin
Zoubeidi, Amina
Reiter, Robert E.
Rettig, Matthew B.
Witte, Owen
Bose, Rohit
Huang, Franklin W.
Fong, Larry
Lara, Primo N.
Evans, Christopher P.
Huang, Jiaoti
Lynch, Molly
Dehm, Scott M. http://orcid.org/0000-0002-7827-5579
Lang, Joshua M. http://orcid.org/0000-0002-0943-8872
Alumkal, Joshi J. http://orcid.org/0000-0003-1278-0166
He, Hansen H. http://orcid.org/0000-0003-2898-3363
Wyatt, Alexander W. http://orcid.org/0000-0003-2399-0329
Aggarwal, Rahul http://orcid.org/0000-0001-7003-7982
Zwart, Wilbert http://orcid.org/0000-0002-9823-7289
Small, Eric J. http://orcid.org/0000-0003-3191-6268
Quigley, David A. http://orcid.org/0000-0002-4726-1473
Lupien, Mathieu
Feng, Felix Y. http://orcid.org/0000-0002-0963-7687
- License Information
-
More Information
Article History
Received: 16 May 2023
Accepted: 10 June 2024
First Online: 17 July 2024
Competing interests
: S.G.Z. has patent applications with Veracyte on molecular signatures in prostate cancer unrelated to this work, and a family member employed by Artera and with stock in Exact Sciences. M.B. has a family member employed by Luminex, a DiaSorin company. A.F. reports personal fees from Varian Medical Systems outside the submitted work. J.R.H. was an employee of Hoffmann-La Roche (Roche Canada) at the time of publication; all contributions for this project were completed before this employment. R.R.A. reports grants from Janssen, Amgen, Zenith Epigenetics and Xynomic Pharmaceuticals; grants and personal fees from AstraZeneca, Merck and Novartis; and personal fees from Dendreon, Elsevier, Exelixis, Jubilant Therapeutics, Bayer, Pfizer and Alessa Therapeutics outside the submitted work. E.J.S. reports other support from Fortis, Harpoon, Teon, Janssen, Johnson & Johnson and Ultragenyx during the conduct of this study; and other support from Fortis, Harpoon, Teon, Janssen, Johnson & Johnson and Ultragenyx outside the submitted work. F.Y.F. reports personal fees from Janssen Oncology, Bayer, PFS Genomics, Myovant Sciences, Roivant Sciences, Astellas Pharma, Foundation Medicine, Varian Medical Systems, Bristol Myers Squibb (BMS), Exact Sciences, BlueStar Genomics, Novartis and Tempus; and other support from Serimmune and Artera outside the submitted work. J.J.A. has received consulting and speaker’s fees from Astellas Pharma, consulting fees from Dendreon, Merck and BMS, and research support to his institution from Zenith Epigenetics and Beactica. S.M.D. reports consulting relationships with BMS, Oncternal Therapeutics, Janssen R&D/Johnson & Johnson and a grant from Pfizer, Astellas and Medivation (the grant was submitted to Medivation, was ultimately funded by Astellas and then moved to Pfizer). The other authors declare no competing interests.
